Vfend (Voriconazole)
voriconazole 40 mg/mL powder for oral liquid, 70 mL · ORAL · PBS code 9452L
AUTHORITY_REQUIREDWhat it costs
AU$439.14 PBS-determined price per 1 units
Most patients pay only the standard PBS co-payment, not the full price above — up to AU$25.00 per script (general) or AU$7.70 (concession/Safety Net) in 2026. The figure above is what the PBS pays the pharmacy; the Australian Government subsidises the rest. Always confirm the current amount with your pharmacist.
- • First listed on the PBS: 2009-08-01.
- • Repeats: 0.
- • PBS program: GE.
Eligibility criteria for subsidised access
The following is the government's own wording from the PBS Schedule, shown unchanged.
Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1
Definite or probable invasive aspergillosis
Treatment and maintenance therapy
Patient must be immunocompromised; AND
Must be treated by a health practitioner who is any of: (i) a medical practitioner, (ii) an authorised PBS prescriber who is not a medical practitioner, but who is: (a) sharing care of the patient with at least one medical practitioner; (b) intending to share care of the patient with a medical practitioner.
Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1
Serious fungal infections
Treatment and maintenance therapy
The condition must be caused by Scedosporium species; or
The condition must be caused by Fusarium species; AND
Must be treated by a health practitioner who is any of: (i) a medical practitioner, (ii) an authorised PBS prescriber who is not a medical practitioner, but who is: (a) sharing care of the patient with at least one medical practitioner; (b) intending to share care of the patient with a medical practitioner.
Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1
Serious Candida infections
Treatment and maintenance therapy
The condition must be caused by species not susceptible to fluconazole; or
The condition must be resistant to fluconazole; or
Patient must be unable to tolerate fluconazole; AND
Must be treated by a health practitioner who is any of: (i) a medical practitioner, (ii) an authorised PBS prescriber who is not a medical practitioner, but who is: (a) sharing care of the patient with at least one medical practitioner; (b) intending to share care of the patient with a medical practitioner.
Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1
Serious invasive mycosis infections
Treatment and maintenance therapy
The treatment must be for invasive mycosis infections other than definite or probable invasive aspergillosis; AND
Must be treated by a health practitioner who is any of: (i) a medical practitioner, (ii) an authorised PBS prescriber who is not a medical practitioner, but who is: (a) sharing care of the patient with at least one medical practitioner; (b) intending to share care of the patient with a medical practitioner.
Sponsor: Pfizer Australia Pty Ltd ABN 50 008 422 348
Not medical advice. Voxsanity republishes public PBS data in plain English. PBS listing status and criteria can change; always confirm current subsidised availability with your doctor or pharmacist.
Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.